Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Statins, cholesterol and cognition at the time of Alzheimer's disease diagnosis : cross-sectional study from the Swedish registry for cognitive/dementia disorders
Avtorji:ID Petek, Bojana (Avtor)
ID Mo, Minjia (Avtor)
ID Xu, Hong (Avtor)
ID Norgren, Jakob (Avtor)
ID Hoang, Minh Tuan (Avtor)
ID Villa-Lopez, Marta (Avtor)
ID Häbel, Henrike (Avtor)
ID Kele, Julianna (Avtor)
ID Naia, Luana (Avtor)
ID Gregorič Kramberger, Milica (Avtor), et al.
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (915,97 KB)
MD5: 7D5F64AF63F47F647EDE66F8C4DF839C
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Background: Evidence suggests statins may influence cognition in Alzheimer's disease (AD), but specific use patterns in AD patients remain unclear. Objective: To identify factors influencing statin use in AD and explore associations between statins, cholesterol, and cognition, evaluated with Mini-Mental State Examination (MMSE) at dementia diagnosis. Methods: A cross-sectional study using data from the Swedish Registry for Dementia and Cognitive Disorders (SveDem) and Stockholm Creatinine Measurements (SCREAM) from 2007 to 2018. Multivariable logistic regression examined associations between baseline characteristics and statin use, while linear regression analyzed relationships between statins, cholesterol levels, and MMSE scores. Results: We included 3074 AD patients (mean age 78.1 years; 59.4% women), of whom 1028 used statins (79.6% simvastatin, 20.4% atorvastatin). Patients with diabetes mellitus, ischemic heart disease, or stroke had greater odds of receiving statins. Older patients had slightly lower odds of receiving any statin at baseline (simvastatin use OR 0.98, 95% CI 0.97–0.99). Simvastatin users had 0.53 points higher MMSE on average at baseline compared to non-users of statins (se 0.23, p = 0.021). Higher low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) levels were associated with higher MMSE in non-users of statins, but not in statin users. Conclusions: Younger AD patients and those with cardiovascular disease were more likely to use statins. Simvastatin use was linked to higher cognitive scores at diagnosis. In non-users, higher LDL-C, TC, and HDL-C levels correlated with better baseline cognitive scores. Longitudinal studies are needed to investigate the effects of statins on cognitive decline in AD.
Ključne besede:Alzheimer's disease, cholesterol, dementia, drug repurposing, mini-mental state examination
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1-13
Številčenje:Vol. 9
PID:20.500.12556/DiRROS-28968 Novo okno
UDK:616.8
ISSN pri članku:2542-4823
DOI:10.1177/25424823251385903 Novo okno
COBISS.SI-ID:253980163 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 21. 10. 2025;
Datum objave v DiRROS:15.04.2026
Število ogledov:102
Število prenosov:46
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Journal of Alzheimer's disease reports
Založnik:IOS Press
ISSN:2542-4823
COBISS.SI-ID:175494659 Novo okno

Gradivo je financirano iz projekta

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Karolinska Institutet
Številka projekta:FoU974639
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Stockholm County council
Številka projekta:FoU961289
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swedish Research Council
Številka projekta:2022-01425
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swedish Research Council
Številka projekta:2020-02014
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swedish Research Council
Številka projekta:2023-02503
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swedish Research Council
Številka projekta:2023-01807
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swedish Research Council
Številka projekta:2024-03573
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swedish Research Council
Številka projekta:2024-03440
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swedish Brain Foundation
Številka projekta:2024-0287
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Karolinska Institutet
Številka projekta:2024-02322
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Swedish Agency for Innovation Systems
Številka projekta:2021-02680
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Karolinska Institutet
Številka projekta:2023-01874
Naslov:/

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Karolinska Institutet
Številka projekta:2022-01282
Naslov:/

Financer:Drugi - Drug financer ali več financerjev

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj